Regulus Therapeutics Inc.

RGLS

US75915K3095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
1.8 ^USD	+2.27%		-11.76%	+40.62%

Jul. 01	Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000E Index	CI
Jul. 01	Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000 Growth Index	CI

Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000 Index

July 30, 2024

Latest news about Regulus Therapeutics Inc.

Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000E Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000 Growth Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell Microcap Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 2500 Value Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell Microcap Growth Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000 Value Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 2000 Value Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000E Growth Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 2000 Growth Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 2000 Dynamic Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell Microcap Value Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 2500 Growth Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 2500 Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000 Index	Jun. 30	CI
Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000E Value Index	Jun. 30	CI
Canaccord Genuity Raises Price Target on Regulus Therapeutics to $28 From $11, Maintains Buy Rating	Jun. 25	MT
HC Wainwright Raises Regulus Therapeutics Price Target to $10 From $9, Maintains Buy Rating	Jun. 25	MT
US Equity Futures Mixed in Premarket Action as Traders Eye Friday's Inflation Data	Jun. 24	MT
Transcript : Regulus Therapeutics Inc. - Special Call	Jun. 24
Regulus Therapeutics Says Potential Kidney Disease Drug Well-Tolerated in Phase 1b Study	Jun. 24	MT
Top Premarket Gainers	Jun. 24	MT
Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Jun. 24	CI
JonesTrading Starts Regulus Therapeutics With Buy Rating, $8 Price Target	May. 31	MT
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration	May. 22	CI

Chart Regulus Therapeutics Inc.

Duration

Period

More charts

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.8 USD

Average target price

11 USD

Spread / Average Target

+511.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGULUS THERAPEUTICS INC.	+40.62%	118M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+18.28%	25.93B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-19.26%	16.01B
BEIGENE, LTD.	-17.95%	15.66B
WUXI APPTEC CO., LTD.	-46.81%	14.89B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B

Bio Therapeutic Drugs